External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology EASL ILC 2023
Roche and Genentech at

EASL ILC 2023

June 21 - June 24
Vienna, Austria
easlcongress.eu
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jun 24 / Roche
Performance of the cobas HBV RNA assay for use on the cobas 5800/6800/8800 Systems (RUO) against genomic variants and transcript heterogeneity
Circulating hepatitis B virus RNA (HBV cirB-RNA) reflects the presence and transcriptional activity of covalently closed circular DNA (cccDNA) and is, therefore, being explored for use as a PCR diagnostic target for monitoring viral clearance and informing treatment decisions. The cobas® HBV RNA assay for use on the cobas 5800/6800/8800 systems (Research-Use Only) targets the 3′ end of cirB-RNA transcribed from HBV cccDNA, allowing differentiation from pregenomic RNA. This study assessed the impact of HBV genomic polymorphisms and transcript diversity on the performance of the assay. The genomic variations and poly-A tail heterogeneity detected in the study had a minimal impact on assay performance. The assay design was improved with additional primers to match rare genomic mismatches.
Infectious Disease Hepatitis B EASL-ILC-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 24 / Roche
Development, Clinical Validation and Implementation of a Novel Algorithmic Score (GAAD) for the Detection of Early-stage Hepatocellular Carcinoma
This study aims to establish and train the algorithm coefficients, and clinically validate the performance of the GAAD algorithm in differentiating HCC and benign chronic liver disease (CLD), across different regions and aetiologies.
Oncology HealthTech Hepatocellular Carcinoma EASL-ILC-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 24 / Roche
A New Biomarker Panel for Differential Diagnosis of Cholangiocarcinoma: Results from an Exploratory Analysis
This study aims to identify individual and combinations of serum tumor biomarkers that could distinguish CCA samples from those with HCC and benign chronic liver disease (CLD) controls using an approach established in a previously published study.
Oncology Cholangiocarcinoma EASL-ILC-2023
10:30 AM
Duration 12mins Vienna, Austria
Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Ahmed Kaseb, Minshan Chen, Pierce Chow, Masatoshi Kudo, Han Chu Lee, Adam Yopp, Lars Becker, Sairy Hernandez, Bruno Kovic, Qinshu Lian, Ning Ma, Chun Wu, Shukui Qin, Ann-Lii Cheng
Oncology | Gastrointestinal Cancer - Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.